Titre du document / Document title

Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection : a pilot study

Auteur(s) / Author(s)

CAMMAROTA G. ⁽¹⁾ ; PAPA A. ⁽¹⁾ ; CIANCI R. ⁽¹⁾ ; CANNIZZARO O. ⁽²⁾ ; ARMUZZI A. ⁽¹⁾ ; GASBARRINI A. ⁽¹⁾ ; ADDOLORATO G. ⁽¹⁾ ; GASBARRINI G. B. ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Department of Internal Medicine, Division of Gastroenterology, Catholic University SC, Rome, ITALIE
⁽²⁾ Madonna della Consolazione' Hospital, Division of Gastroenterology, Reggio Calabria, ITALIE

Résumé / Abstract

Objective The aim of the present study was to investigate and compare the effects of two proton-pump inhibitors, lansoprazole (Limpidex 30 mg, Sigmatau) vs pantoprazole (Peptazol 40 mg, Boehringer Mannheim), included in a three-day antibiotic therapy regimen with azithromycin (Zitromax 500 mg, Pfizer) and tinidazole (Fasigin 500 mg, Pfizer). Design Seventy consecutive, H. pylori-positive patients were randomly pre-treated with lansoprazole 30 mg o.d. (once daily) or pantoprazole 40 mg o.d. for two days, and subsequently respectively assigned to one of the two following treatment regimens, given for only three days: regimen A (LAT) comprising lansoprazole 30 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. (bis in die), or regimen B (PAT) comprising pantoprazole 40 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. H. pylori status was evaluated by means of histology and rapid urease test at entry, and by ¹³C-urea breath test alone 8 weeks after treatment. Main outcome measures Sixty-nine of the enrolled patients completed the study: 34 in the LAT group and 35 in the PAT group. One patient in the LAT group was lost to follow-up. In the LAT group, after the end of treatment, 28/ 34 patients were H. pylori-negative (per protocol: 82%; intention-to-treat: 80%). In the PAT group, after treatment, 29/35 patients were H. pylori-negative (per protocol and intention-to-treat: 83%). Mild or slight side-effects occurred in only one patient in the LAT group and in one in the PAT group. Conclusions From this study there is no evidence that either of the two proton-pump inhibitors used is preferable in a three-day antibiotic regimen with azithromycin and tinidazole. The excellent side-effect and tolerability profiles, associated with acceptable eradication rates, make the two treatment regimens we tested particularly useful when patient compliance is difficult to achieve.

Revue / Journal Title

European journal of gastroenterology & hepatology   ISSN 0954-691X 

Source / Source

1999, vol. 11, n^o3, pp. 247-250 (31 ref.)

Langue / Language

Anglais

Editeur / Publisher

Lippincott Williams & Wilkins, Hagerstown, MD, ETATS-UNIS  (1989) (Revue)

Mots-clés anglais / English Keywords

Gastritis ; Bacteriosis ; Helicobacter pylori ; Chemotherapy ; Antibacterial agent ; Azithromycin ; Tinidazole ; Drug combination ; Proton pump inhibitor ; Lansoprazole ; Pantoprazole ; Processing time ; Short lasting ; Comparative study ; Treatment efficiency ; Human ; Imidazole derivatives ; Nitro compound ; Benzimidazole derivatives ; Infection ; Spirillaceae ; Spirillales ; Bacteria ; Digestive diseases ; Gastric disease ;

Mots-clés français / French Keywords

Gastrite ; Bactériose ; Helicobacter pylori ; Chimiothérapie ; Antibactérien ; Azithromycine ; Tinidazole ; Association médicamenteuse ; Inhibiteur pompe proton ; Lansoprazole ; Pantoprazole ; Temps traitement ; Courte durée ; Etude comparative ; Efficacité traitement ; Homme ; Imidazole dérivé ; Composé nitro ; Benzimidazole dérivé ; Infection ; Spirillaceae ; Spirillales ; Bactérie ; Appareil digestif pathologie ; Estomac pathologie ;

Mots-clés espagnols / Spanish Keywords

Gastritis ; Bacteriosis ; Helicobacter pylori ; Quimioterapia ; Antibacteriano ; Azitromicina ; Tinidazol ; Asociación medicamentosa ; Inhibidor bomba protón ; Lansoprazol ; Pantoprazol ; Tiempo proceso ; Corta duración ; Estudio comparativo ; Eficacia tratamiento ; Hombre ; Imidazol derivado ; Compuesto nitro ; Benzimidazol derivado ; Infección ; Spirillaceae ; Spirillales ; Bacteria ; Aparato digestivo patología ; Estómago patología ;

Localisation / Location

INIST-CNRS, Cote INIST : 22107, 35400008339245.0070